Notable paper: immune signatures in CRC identifying overlapping features associated with good patient prognosis including tertiary lymphoid organs, specialized endothelial cells (HEV), T and B cell signatures and IL15. Also looks at immunosuppression. nature.com/articles/s4301…

Folks to see the actual impact of IRA price cuts you need to compare to prices minus rebates as detailed here and published: jmcp.org/doi/10.18553/j…

Take notice humans. Gen J is cool instagram.com/stories/yiume_…

Table from ApexOnco #ASCO24 CAR-GPC3 for HCC coverage. >But no new data from CARsGen CT0801. >AbleZeta excluded patients with active HBV or HCV while CARsGen specifically enrolled HCV+ patients. >R other CARs segregating by HCC cause (viral v metabolic)? >any new CT0801 data?

WHAT HAPPENED TO EUREKA THERAPEUTICS anyone?

Hold and Kill: Halda Raises $126M toward Precision Cancer Treatments Craig Crews-founded startup eyes 2025 trial for lead candidate, based on regulated induced proximity targeting chimeras (RIPTAC™) platform. Learn more: hubs.li/Q02LFvdk0

Anyone know what happened to EUREKA Therapeutics? They seem to have left w/o a trace...

ANYONE seen updated data from the CARsgen Therapeutics CT0180 trial in HBV-positive HCC (liver cancer)?

The U.S. FDA approved the targeted therapy lazertinib in combination with the bispecific antibody amivantamab-vmjw for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with certain EGFR mutations: bit.ly/3yJtGMm

NOT GOOD science.org/content/articl…

some heavy weather on the Cape

and again

and a third

Xencor has terminated developed of IL-12-Fc, a reduced potency cytokine fusion protein. #XmAb662 had been in a solid tumor basket study with #pembrolizumab. $XNCR clinicaltrials.gov/study/NCT05996…

VEGF is one of the three big sticks to pair with PD-1 inhibitors to beat cancer. The other two, so far poorly used, are TGFbeta and beta-catenin. Degraders will be useful here.

Awaiting ex-China data … but yes